curasafehealthcare.com
  • Home
  • About
  • Services
  • Therapeutic Areas
  • Careers
  • Latest News
  • Contact Us
Select Page
Researchers discover race-associated molecular differences in pancreatic tumors

Researchers discover race-associated molecular differences in pancreatic tumors

by palligoelme@gmail.com | Mar 13, 2025 | Clinical Trials

​  Researchers have discovered race-associated molecular differences in tumors that may impact the way patients with pancreatic cancer respond to immunotherapies.  Researchers have discovered race-associated molecular differences in tumors that may impact the way...
China Medical University Hospital Joins With AbbVie to Promote Innovative Clinical Trial Collaboration

China Medical University Hospital Joins With AbbVie to Promote Innovative Clinical Trial Collaboration

by palligoelme@gmail.com | Mar 13, 2025 | Clinical Trials

​  Li-Yuan Bai, M.D., M.M.S., Ph.D.  Li-Yuan Bai, M.D., M.M.S., Ph.D. 
GC Cell Initiates First Patient Dosing in Phase 1 Clinical Trial for GCC2005, a Promising T‑Cell Lymphoma CD5 CAR-NK Therapy

GC Cell Initiates First Patient Dosing in Phase 1 Clinical Trial for GCC2005, a Promising T‑Cell Lymphoma CD5 CAR-NK Therapy

by palligoelme@gmail.com | Mar 12, 2025 | Clinical Trials

​  /PRNewswire/ — GC Cell (KRX:144510), under the leadership of CEO Sungyong Won, announced today the initiation of its domestic Phase 1 clinical trial for…  /PRNewswire/ — GC Cell (KRX:144510), under the leadership of CEO Sungyong Won, announced...

Research on the Improvement of Intestinal and Immune Functions by Probiotics

by palligoelme@gmail.com | Mar 12, 2025 | Clinical Trials

​ Conditions: Intestinal Health Interventions: Dietary Supplement: Probiotic; Dietary Supplement: Placebo Sponsors: Wecare Probiotics Co., Ltd. Not yet recruiting Conditions: Intestinal Health Interventions: Dietary Supplement: Probiotic; Dietary Supplement: Placebo...
Expert Explores Trials in CIS-Refractory Bladder Cancer

Expert Explores Trials in CIS-Refractory Bladder Cancer

by palligoelme@gmail.com | Mar 12, 2025 | Clinical Trials

​  Jason M. Hafron, MD, CMO, discusses recent approvals in the non–muscle-invasive bladder cancer space and data from several clinical trials evaluating agents for bladder cancer.  Jason M. Hafron, MD, CMO, discusses recent approvals in the non–muscle-invasive bladder...
Advarra Unveils Oncology Research Pulse

Advarra Unveils Oncology Research Pulse

by palligoelme@gmail.com | Mar 12, 2025 | Clinical Trials

​  /PRNewswire/ — Advarra, the market leader in regulatory review solutions and clinical research technology, today announced the launch of Oncology Research…  /PRNewswire/ — Advarra, the market leader in regulatory review solutions and clinical...
« Older Entries
Next Entries »

Recent Posts

  • Smart 3: A Multi-Center Phase 2 Trial Of Golcadomide, Glofitamab And Polatuzumab Vedotin (G2P) For Patients With Newly Diagnosed Large B-Cell Lymphoma
  • Safety, Tolerability, and Clinical Effectiveness of Adapalene/Clindamycin Phosphate Gel (Klenzit®-C) in Vietnamese Patients With Mild to Moderate Acne Vulgaris
  • A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010)
  • Effect of Autologous Serum-Soaked Paper Patch vs. Traditional Dry Paper Patch on Tympanic Membrane Perforations
  • Use of cfDNA in Monitoring and Guiding Treatment for Cervical Cancer

Recent Comments

No comments to show.

Curasafe healthcare solutions Pvt. Ltd. provides comprehensive services including safety program oversight, risk management, and regulatory compliance.

Important Links

  • Home
  • Contact Us
Connect With Us

Contact


711, Shivalik Satyamev, Bopal Ambli Junction, Bopal, Ahmedabad, Daskroi, Gujarat, India, 380058.


info@curasafehealthcare.com



(+91) 97803 81065

Copyright © 2025 Curasafehealthcare ®